Berlin, 7 June 2023. At today's Annual General Meeting of Eckert & Ziegler AG, the shareholders approved the proposal of the Executive Board and Supervisory Board to distribute a dividend of 0.50 EUR per dividend-bearing share. All items on the agenda were accepted by the shareholders. A total of 57.75% of the share capital of Eckert & Ziegler AG was represented at the Annual General Meeting.

At the end of the Annual General Meeting, the former Chairman of the Executive Board and founder Dr. Andreas Eckert (63) moved to the Supervisory Board. As planned, Dr. Harald Hasselmann (56), member of the Executive Board and responsible for the Medical segment, thus takes over as Chairman of the Executive Board. The long-standing Chairman of the Supervisory Board, Prof. Dr. Wolfgang Maennig, left the Supervisory Board at the end of the Annual General Meeting.

At his own request and as part of an early retirement arrangement, Dr. Lutz Helmke is leaving the Executive Board. Newly appointed to the Executive Board and responsible for the Isotopes segment is the long-time head of this division, Frank Yeager, who is based in California. The Executive Board positions of Dr. Hakim Bouterfa and Jutta Ludwig remain unaffected by the changes. A new member of the Executive Committee will be Ana Ramirez, for many years General Manager within the Isotope Products segment and responsible, among others, for the Latin American business.

The documents and voting results for the Annual General Meeting are available at

About Eckert & Ziegler.
Eckert & Ziegler Strahlen- und Medizintechnik AG with more than 1.000 employees is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.

Your contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, ,